SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who started this subject8/29/2000 4:41:42 AM
From: nigel bates  Read Replies (1) of 278
 
Don't know anything about this one, but it's certainly a propos the previous posts (note they helped fund some of the work cited earlier).

Aug. 29 /PRNewswire/ -- After British studies revealed a much greater potential for the spread of fatal brain diseases such as Creutzfeldt-Jakob Disease, the human variant of Mad Cow Disease, Australian-based Prana Biotechnology Limited has today announced it may have the technology to help develop a treatment. The technology arises out of discoveries made at the Department of Pathology at the University of Melbourne in Australia.
The British researchers' announcement by the London-based Medical Research Council is of concern for health authorities as it shows the diseases could be more widespread than previously thought and that healthy appearing animals can be carriers of the disease.
In the UK the incidence of these diseases is increasing at an alarming rate of 20 to 30% per annum. There is currently no available cure for this fatal disease. Mad Cow Disease entered the human food chain in 1996 leading to a collapse of the entire United Kingdom beef trade at the time.
``Prana Biotechnology has commenced phase II clinical trials for the treatment of Alzheimer's Disease that could be used for Creutzfeldt-Jakob Disease,'' said Mr. Geoffrey Kempler, Executive Chairman of Prana Biotechnology.
``Prana has the potential to be the first to progress to clinical trials. We will now accelerate pre-clinical work on development of a therapeutic treatment for the prevention of Creutzfeldt-Jakob Disease.
``The latest finding by the British researchers suggests that the risk of Creutzfeldt-Jakob Disease is greater than previously thought and this makes development of a treatment a more urgent priority.''
Prana Biotechnology's work is based on its discoveries about the relationship between aggregation-prone proteins susceptible to metal-mediated oxidative stress. In the case of Alzheimer's Disease the target protein is Amyloid, in Creutzfedt-Jakob disease it is the Prion protein, which in many ways resembles the Amyloid protein of Alzheimer's Disease.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News